A61B17/52

MAGNETIC IMPLANT FOR JOINT FIXATION AND METHOD
20180014838 · 2018-01-18 ·

The present invention provides for a joint fixation device and method utilizing magnetic members with at least one magnetic member positioned on each of opposite sides of a joint and secured to skeletal components. The magnetic members include at least one permanent magnet. The magnetic members can be configured to provide an attracting force or a repelling force. They can also be configured to provide a torque about the joint.

Method and apparatus for determining effects of transcranial magnetic stimulation to a brain
09696387 · 2017-07-04 · ·

The present invention relates generally to a method and apparatus for determining one or more cumulative effects of an application of transcranial magnetic stimulation to the brain of a subject, as well as a method and apparatus of representing same. According to an aspect of certain embodiments of the invention there is provided a method for determining one or more cumulative effects of an application of transcranial stimulation to one or more locations in a brain of a subject comprising the steps of applying multiple transcranial magnetic stimulation pulses to the brain, determining a dose of each of said stimulation pulses, measuring a physical response of the user and determining or approximating an accumulation of said response of said brain for each of said one or more locations in the brain of said subject.

Magnetic vaginal dilator

Aspects of the present invention are related to magnetic medical devices for the treatment of chronic medical conditions such as Vulvodynia, Vaginismus, Vaginal Stenosis, Vaginal Atrophy, among others. The magnetic medical device in accordance with the present invention is of a generally elongated shape having an ogive top end, a middle portion of an active diameter, and a bottom end of a passive diameter. The magnetic medical device has an array of magnets within, where the magnets generate a negative magnetic field adjacent to an external surface of the magnetic medical device.

Beauty tool
09615854 · 2017-04-11 · ·

A beauty tool (1) includes: a substantially rod-shaped main body (10); an attraction head (2) provided in the main body (10); and a beauty effect imparting part for imparting a beauty effect to human skin in a state where it is in contact with or close to the human skin. The attraction head (2) is provided at one end of the main body (10) and includes a magnetic force generating surface (20) for attracting and removing, by means of a magnetic force, a cosmetic agent applied to the human skin.

Beauty tool
09615854 · 2017-04-11 · ·

A beauty tool (1) includes: a substantially rod-shaped main body (10); an attraction head (2) provided in the main body (10); and a beauty effect imparting part for imparting a beauty effect to human skin in a state where it is in contact with or close to the human skin. The attraction head (2) is provided at one end of the main body (10) and includes a magnetic force generating surface (20) for attracting and removing, by means of a magnetic force, a cosmetic agent applied to the human skin.

REVERSIBLE TATTOO COLORANT AND METHOD
20170035461 · 2017-02-09 ·

A tattoo ink or colorant has magnetic properties. The ink is delivered to the proper depth of the skin. The colorant remains in place, forming the desired visible design. When removal of the tattoo is desired, a magnet is topically applied to draw the ink or colorant to move the nanoparticles to the epidermis. The nanoparticles are then shed from the epidermis along with squamous cell debris.

REVERSIBLE TATTOO COLORANT AND METHOD
20170035461 · 2017-02-09 ·

A tattoo ink or colorant has magnetic properties. The ink is delivered to the proper depth of the skin. The colorant remains in place, forming the desired visible design. When removal of the tattoo is desired, a magnet is topically applied to draw the ink or colorant to move the nanoparticles to the epidermis. The nanoparticles are then shed from the epidermis along with squamous cell debris.

Affinity peptide-modified particles and targeted drug delivery methods

A therapeutic particle comprises a particle comprising one or more therapeutic agents and one or more fibrin-avid peptide variants attached to the surface of the particle. A method for magnetically targeting a therapeutic agent toward a device in a subject, such as a temporarily introduced magnetizable catheter or an implanted stent, comprises administering the therapeutic particles to the subject and generating a magnetic field, which targets the magnetic particles toward the device. The affinity peptide-modified therapeutic particles may comprise an effective amount of an anti-proliferative agent, such as paclitaxel, to inhibit or prevent in-stent restenosis.

Resident articles for gram-level dosing

Drug delivery articles, resident articles, and retrieval systems e.g., for gram-level dosing, are generally provided. In some embodiments, the articles are configured for transesophageal administration, transesophageal retrieval, and/or gastric retention to/in a subject. In certain embodiments, the article includes dimensions configured for transesophageal administration with a gastric resident system. In some cases, the article may be configured to control drug release e.g., with zero-order drug kinetics with no potential for burst release for weeks to months. In some embodiments, the articles described herein comprise biocompatible materials and/or are safe for gastric retention. In certain embodiments, the article includes dimensions configured for transesophageal retrieval. In some cases, the articles described herein may comprise relatively large doses of drug (e.g., greater than or equal to 1 gram).

Resident articles for gram-level dosing

Drug delivery articles, resident articles, and retrieval systems e.g., for gram-level dosing, are generally provided. In some embodiments, the articles are configured for transesophageal administration, transesophageal retrieval, and/or gastric retention to/in a subject. In certain embodiments, the article includes dimensions configured for transesophageal administration with a gastric resident system. In some cases, the article may be configured to control drug release e.g., with zero-order drug kinetics with no potential for burst release for weeks to months. In some embodiments, the articles described herein comprise biocompatible materials and/or are safe for gastric retention. In certain embodiments, the article includes dimensions configured for transesophageal retrieval. In some cases, the articles described herein may comprise relatively large doses of drug (e.g., greater than or equal to 1 gram).